Precision Biosciences (DTIL) Net Income towards Common Stockholders (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$8.6 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 59.69% year-over-year to -$8.6 million in Q1 2026; TTM through Mar 2026 was -$46.0 million, a 22.07% increase from a year earlier, with the FY2025 full-year figure at $885000.0, changed N/A from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$8.6 million, down from $12.4 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for DTIL reached as high as $15.6 million in Q2 2024 and fell as low as -$35.9 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$12.6 million across 5 years, with a median of -$9.1 million in 2022.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 275.73% in 2024 and fell as far as 830.94% in 2024.
• Year by year, Net Income towards Common Stockholders stood at -$9.1 million in 2022, then soared by 68.49% to -$2.9 million in 2023, then tumbled by 735.38% to -$23.8 million in 2024, then soared by 151.96% to $12.4 million in 2025, then tumbled by 169.19% to -$8.6 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$8.6 million in Q1 2026, $12.4 million in Q4 2025, and -$27.6 million in Q3 2025.